Assessment of Protocol Impact on Subjectivity Uncertainty When Analyzing Peripheral Blood Mononuclear Cell Flow Cytometry Data Files

Abstract

Measured variability of product within Cell and Gene Therapy (CGT) manufacturing arises from numerous sources across pre-analytical to post-analytical phases of testing. Operators are a function of the manufacturing process and are an important source of variability as a result of personal differences impacted by numerous factors. This research uses measurement uncertainty in comparison to Coefficient of Variation to quantify variation of participants when they complete Flow Cytometry data analysis through a 5-step gating sequence. Two study stages captured participants applying gates using their own judgement, and then following a diagrammatical protocol, respectively. Measurement uncertainty was quantified for each participant (and analysis phase) by following Guide to the Expression of Uncertainty in Measurement protocols, combining their standard deviations in quadrature from each gating step in the respective protocols. When participants followed a diagrammatical protocol, variation between participants reduced by 57%, increasing confidence in a more uniform reported cell count percentage. Measurement uncertainty provided greater resolution to the analysis processes, identifying that most variability contributed in the Flow Cytometry gating process is from the very first gate, where isolating target cells from dead or dying cells is required. This work has demonstrated the potential for greater usage of measurement uncertainty within CGT manufacturing scenarios, due to the resolution it provides for root cause analysis and continuous improvement.

Computational deconvolution of fifteen leukocyte subtypes from DNA methylation microarrays trained on flow cytometry data in the Health and Retirement Study

“…However, this approach is flawed without a gold standard or if said standard comes with substantial measurement error. As with all laboratory measures, there may be measurement error in flow cytometry counts [18]. Instead, we assess model performance by quantifying how much of the variance in whole blood DNAm levels is explained by the various cell proportion estimates.…”

Mannose-modified erythrocyte membrane-encapsulated chitovanic nanoparticles as a DNA vaccine carrier against reticuloendothelial tissue hyperplasia virus

“…Isolated lymphocytes (2×10 6 cells/mL; 50 μL) were stained using mouse anti-chicken CD3 + -allophycocyanin (APC), CD4 + -fluorescein isothiocyanate (FITC), and CD8 + -phycoerythrin (PE) fluorescent antibodies. The percentage of CD4 + and CD8 + T lymphocytes in T cells was measured by florescence-activated cell sorting (FACS; BD FACSVerseTM, CA, USA), and the ratio of CD4 + /CD8 + T cells was calculated ( 21 ).…”

Neutrophil extracellular traps and cancer-associated thrombosis

“…Flow cytometry assays detecting NET components on cells or EVs have also been proposed for the assessment of NET formation in vivo in both animal models and humans [25,36]. However, these methods are hampered by a lack of standardization and operator subjectivity during the data-analysis stage [37]. Enzyme-linked immunosorbent assays (ELISAs), both commercial and in-house, can be used to quantify NET components in blood.…”